-
2024-09-02◆◆
1、會(huì)議年份：2024年
2、會(huì)議主題：①ASCO Annual Meeting、②ASCO Gastrointestinal Cancers Symposium、
③ASCO Genitourinary Cancers Symposium 、④Best of ASCO、⑤ASCO Breakthrough
3、說明：合計(jì)5個(gè)主題的原始全文內(nèi)容查詢，每個(gè)主題單獨(dú)中標(biāo)，具體可以單獨(dú)溝通。
已結(jié)束 -
2023-02-09◆◆
求藥物的代謝、吸收、排泄、毒性、理化、轉(zhuǎn)運(yùn)體數(shù)據(jù)源網(wǎng)站
（具體詳見附件，提供的數(shù)源網(wǎng)站必須包含附件中標(biāo)紅的部分，其次提供的數(shù)據(jù)源網(wǎng)站必須是非商業(yè)化網(wǎng)站）
注：需求內(nèi)容等相關(guān)內(nèi)容可以聯(lián)系具體交流
已結(jié)束 -
2023-01-11◆◆
需求目前全球已上市和臨床在研化藥的藥代動(dòng)力學(xué)數(shù)據(jù)資源，其中提供的信息需包含表中的數(shù)據(jù)內(nèi)容（注：數(shù)據(jù)信息需要有一定的準(zhǔn)確性，可提供相關(guān)網(wǎng)站鏈接，也可以提供具體數(shù)據(jù)）
備注：需求內(nèi)容等相關(guān)內(nèi)容可以聯(lián)系具體交流
已結(jié)束 -
2019-11-26◆◆
提供藥廠及藥品轉(zhuǎn)讓項(xiàng)目/合作項(xiàng)目，需要具體的轉(zhuǎn)讓信，企業(yè)名稱，聯(lián)系方式，信息需真實(shí)可靠。
已結(jié)束 -
2019-04-01◆◆
提供藥廠及藥品轉(zhuǎn)讓項(xiàng)目/合作項(xiàng)目，需要具體的轉(zhuǎn)讓信，企業(yè)名稱，聯(lián)系方式，信息需真實(shí)可靠。
已結(jié)束 -
2019-01-08◆◆
提供藥廠及藥品轉(zhuǎn)讓項(xiàng)目/合作項(xiàng)目，需要具體的轉(zhuǎn)讓信，企業(yè)名稱，聯(lián)系方式，信息需真實(shí)可靠。
已結(jié)束 -
2018-12-18◆◆
文獻(xiàn)標(biāo)題及相關(guān)內(nèi)容： 1.Ohmukai O.Lipo- NSAID preparation[J].Adv Drug Deliv Rev 2.Less pain on injection by a new formulation of propofol? A comparison with propofol LCT 3.Tohno, M.，Konishi , Y.，Kojima , H., Kawahara, K. and Horiba, M. (1992 ) Pharmacokinetics and metabolic studies of LFP83 in man after the single and repeated intravenous administration. Clin. Rep. 26, 3907-3921. 4.Naito, Y. et al.：Arzneim.-Forsch.Drug Res., 46(II), 698-700, 1996 5.What is the Role of NSAIDs in Pre-emptive Analgesia?
已完成 -
2018-12-17◆◆
文獻(xiàn)標(biāo)題及相關(guān)信息 1：Fluconazole-related hepatotoxicity in patients with acquired immunodeficiency syndrome 2：Tohno, M.，Konishi , Y.，Kojima , H., Kawahara, K. and Horiba, M. (1992 ) Pharmacokinetics and metabolic studies of LFP83 in man after the single and repeated intravenous administration. Clin. Rep. 26, 3907-3921. 3：Targeting Vascular Endothelial-?Cadherin in Tumor-?Associated Blood Vessels Promotes T-?cell-?Mediated Immunotherapy 4：Therapeutic regulation of VE-?cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models
已完成 -
2018-11-29◆◆
文獻(xiàn)標(biāo)題及相關(guān)信息如下： 1.Safety data for chemical products-Content and order of sections［s］ ． ISO 11014-2009， 2009 2.ZHANG Li， LU Ying． Problems incountering for danger chemicals registing work in Jiangsu［J］ ． Chemical Safety ＆ Environment，2007， 1( 12) : 8-12 3.EU， Regulation( EC) No 1272 /2008 of European Parliament and of the Council of 16 December 2008 on classification， labelling and packing of substances and amending Regulation( EC) No1907 /2006［z］， 2008 4.Hazard Communication． 29 CFR 1910. 1200 5.SHA Xi-dong，JIANG Hong， LI Li-xia． Study on classification of major hazard installation of hazardous chemicals［J］ ． Journal of Safety Science and Technology， 2011，7 ( 3) : 37-41 備注：提供PDF電子檔原件
已完成 -
2018-11-07◆◆
1、Analytical method transfer using equivalence tests with reasonable acceptance criteria and appropriate effort: extension of the ISPE concept 2、Using total error as decision criterion in analytical method transfer 3、Application of the equivalence test according to a concept for analytical method transfers from the International Society for Pharmaceutical Engineering (ISPE) 4、Application of the equivalence test for analytical method transfers: Testing precision using the United States Pharmacopoeia concept< 1 0 1 0 5、Blade-Font, Artur; Rocabayera, Teodoro de Mas - [Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1982, p. 841 - 848]
已完成
- 10
- 交易量
- 9950
- 賞金
-
藥智客
08-27 14:21 -
藥智客
08-18 12:49 -
藥智客
08-17 13:57 -
藥智客
08-15 22:06 -
藥智客
08-12 04:08 -
藥智客
08-09 13:46 -
藥智客
08-08 18:46 -
藥智客
08-07 03:52 -
藥智客
08-06 04:36 -
藥智客
07-25 12:33
